Small molecule inhibitors of DDX21 could be developed with helicase targeting strategies similar to the discovery of DDX3 and DDX41 inhibitors [12, 13, 14], one of which (DDX3 inhibitor, RK‐33) is currently in a clinical trial in lung cancer patients. This evidence concerns the gene DDX21 and lung carcinoma.